Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/1S1 stock hub

FRA/1S1 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/1S1is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.5B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/1S1FRA/1S1

—

Loading chart…

In the news

Latest news · FRA/1S1

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-58.1

P25 n/aP50 n/aP75 n/a

ROIC-36.6

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/1S1 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

159

Groups with data

Currency

USD

Showing 159 of 159 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	252
Employees Change	49%
Employees Change Percent	52.13
Enterprise value	EUR 964.5M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.5B
Price	EUR 14.3
Price currency	EUR
Rev Per Employee	244,076.12x
Sic	2836
Symbol	fra/1S1
Website	https://www.viridiantherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-18.08%
EV Earnings	-3.67x
EV/FCF	-3.66x
EV/Sales	16.01x
FCF yield	-18.12%
P/B ratio	2.64x
P/S ratio	23.65x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	EUR -233.1M
Net Income	EUR -263M
Pretax Margin	-508.46%
Profit Per Employee	EUR -1M
ROA	-33.25
Roa5y	-29.68
ROCE	-52.32
ROE	-58.14
Roe5y	-50.12
ROIC	-36.61

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	32.43%
Cagr3y	-16.54%
Cagr5y	0.14%
Revenue Growth	23,382.78x
Revenue Growth Q	95.83x
Revenue Growth3 Y	250x
Revenue Growth5 Y	111.57x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.1
Assets	EUR 684.3M
Cash	EUR 661M
Current Assets	EUR 665.4M
Current Liabilities	EUR 43.9M
Debt	EUR 46.3M
Debt Equity	EUR 0.08
Debt FCF	EUR -0.18
Equity	EUR 551.6M
Interest Coverage	-49.07
Liabilities	EUR 132.7M
Long Term Assets	EUR 18.9M
Long Term Liabilities	EUR 88.8M
Net Cash	EUR 614.8M
Net Cash By Market Cap	EUR 42.26
Net Cash Growth	15.53%
Net Debt Equity	EUR -1.11
Tangible Book Value	EUR 437.1M
Tangible Book Value Per Share	EUR 4.27

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	15.15
Net Working Capital	EUR -24.7M
Quick ratio	14.71
Working Capital	EUR 635.7M
Working Capital Turnover	EUR 0.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-23.41%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	32.41%
200-day SMA	20.57
3Y total return	-41.87%
50-day SMA	18.46
50-day SMA vs 200-day SMA	50under200
5Y total return	0.7%
All Time High	230.3
All Time High Change	-93.79%
All Time High Date	2017-03-06
All Time Low	3.57
All Time Low Change	300.56%
All Time Low Date	2020-03-19
ATR	0.76
Ch YTD	-45.75
High	14.3
High52	28.58
High52 Date	2026-01-15
High52ch	-49.97%
Low	14.3
Low52	10.86
Low52 Date	2025-05-15
Low52ch	36.91%
Ma50ch	-22.55%
Price vs 200-day SMA	-30.48%
RSI	48.94
RSI Monthly	45.07
RSI Weekly	32.83
Sharpe ratio	0.66x
Sortino ratio	1.02
Total Return	-23.41%
Tr YTD	-45.75
Tr1m	17.21%
Tr1w	26.55%
Tr3m	-41.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -334.5M
Operating margin	-543.9

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	97,599,026%
Net Borrowing	24,484,902.8
Shares Insiders	0.06%
Shares Institutions	100.85%
Shares Qo Q	8.3%
Shares Yo Y	23.41%
Short Ratio	4.01

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -304.7M
Average Volume	116.95x
Bv Per Share	4.27
CAPEX	EUR -374,674
Ch1m	17.21
Ch1w	26.55
Ch1y	32.41
Ch3m	-41.25
Ch3y	-41.87
Ch5y	0.7
Ch6m	-39.23
Change	-2.72%
Change From Open	0
Close	14.7
Days Gap	-2.72
Depreciation Amortization	393,454.4
Earnings Date	2026-08-07
EBIT	EUR -334.5M
EBITDA	EUR -334.1M
EPS	EUR -2.92
F Score	1
FCF	EUR -263.5M
FCF EV Yield	-27.32x
Financing CF	367,637,195
Fiscal Year End	December
Founded	2,010
Investing CF	-52,353,697
Is Primary Listing	0
Last Earnings Date	2026-02-27
Last Report Date	2026-03-31
Last Split Date	2020-11-13
Last Split Type	Reverse
Ma150	22.24
Ma150ch	-35.69%
Ma20	12.54
Ma20ch	14.04%
Net CF	52,151,616
Next Earnings Date	2026-08-07
Open	14.3
Ppne	2,870,351.4
Price Date	2026-05-08
Ptbv Ratio	3.33
Relative Volume	2.38x
Revenue	61,507,181x
SBC By Revenue	66.94x
Share Based Comp	41,173,333
Tr6m	-39.23%
Volume	0
Z Score	4.88

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/1S1 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/1S1 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/1S1?

Insider, institutional, and short-interest positioning.

Institutional ownership

+100.9%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/1S1 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.9

Neutral momentum band

Price vs 200-day MA

-30.5%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.66

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/1S1

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/1S1 stock rating?

fra/1S1 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/1S1 analysis?

The full report lives at /stocks/fra/1S1/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/1S1?

The latest report frames fra/1S1 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/1S1 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.